Abstract: Recently, the immunological checkpoint inhibitors (ICIs) represented by programmed death-1/ program-med cell death-ligand 1 antibody have shown dramatic efficacy in advanced gastric adenocarcinoma. Although the overall response rate is not high, great tumor regression and long-term control can be reported in particular population. More interestingly, efficacy and good tolerance are also documented in adjuvant or neo-adjuvant treatments of lung cancer or other tumors. However, the rationality and feasibility of ICIs in perioperative treatments for locally advanced gastric cancer are not yet clear. This review will provide basic data for future clinical research and practice.